What does the evidence say about Akkermansia Muciniphila Supplement?

The current Migaku evidence database contains 2 reusable source documents for Akkermansia Muciniphila Supplement. This answer focuses on benefits, uncertainty, and practical interpretation. - 1 2 3 4 5 The global burden of type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) continues to rise at an alarming pace. [Dinkov Boris (2026); evidence level 3] - MASLD may progress to metabolic dysfunction-associated steatohepatitis (MASH), characterized by hepatocellular injury, lobular inflammation, and fibrosis, which significantly increases the risk of cirrhosis and hepatocellular carcinoma []. [Dinkov Boris (2026); evidence level 3] - A growing body of preclinical and clinical evidence indicates that GLP-1-based therapies exert significant modulatory effects on the composition and function of the gut microbiome, which may indirectly contribute to their hepatoprotective properties. [Dinkov Boris (2026); evidence level 3] - Current estimates indicate that approximately 589 million people worldwide are living with diabetes, with T2DM accounting for over 90% of cases []. [Dinkov Boris (2026); evidence level 3] - According to the Global Burden of Disease study, the incidence of such disorders has increased in recent decades, particularly in developed nations (;). [Xie Luyu (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.